Los Angeles Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Los Angeles Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$457K	Sell	1,364 -3,696	-73%	-$1.17M	﹤0.01%	935
2026 Q1	$1.63M	Buy	5,060 +4,508	+817%	+$1.39M	0.01%	553
2025 Q4	$111K	Buy	+552	New	+$103K	﹤0.01%	1393
2023 Q2	–	Sell	-17,592	Closed	-$213K	–	1261
2023 Q1	$213K	Buy	17,592 +8,770	+99%	+$370K	﹤0.01%	1111
2022 Q4	$315K	Buy	8,822 +1,748	+25%	+$54.5K	﹤0.01%	1025
2022 Q3	$241K	Sell	7,074 -89	-1%	-$4.43K	﹤0.01%	1136
2022 Q2	$263K	Buy	+7,163	New	+$764K	﹤0.01%	1188
2021 Q3	–	Sell	-1,173	Closed	-$322K	–	1569
2021 Q2	$322K	Sell	1,173 -56	-5%	-$20.1K	﹤0.01%	1364
2021 Q1	$604K	Buy	+1,229	New	+$874K	﹤0.01%	1126

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Los Angeles Capital Management's PRAX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 73% in Q2 2026, selling an estimated $1.17M and leaving 1,364 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Los Angeles Capital Management first reported a position in PRAX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.63M in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Los Angeles Capital Management held 1,364 shares of Praxis Precision Medicines worth $457K as of Q2 2026.
Los Angeles Capital Management sold 3,696 Praxis Precision Medicines shares in Q2 2026, an estimated $1.17M.
Praxis Precision Medicines made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #935 holding.
Los Angeles Capital Management first reported a position in Praxis Precision Medicines in Q1 2021 and has held it in 9 quarters since.
Los Angeles Capital Management's Praxis Precision Medicines position peaked at $1.63M in Q1 2026.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.